Immunization Safety Review: Vaccines and Autism Marie McCormick Chair, Immunization Safety Review Committee Presentation to NVAC June 2004.

Slides:



Advertisements
Similar presentations
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Advertisements

Study Objectives and Questions for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Deriving Biological Inferences From Epidemiologic Studies.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
VACCINE SAFETY: 101 Pandemic Influenza Vaccine Safety Conference Atlanta, Georgia August 21, 2008.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Study Designs in Epidemiologic
1 High Production Volume (HPV) Challenge Program – Future Directions Jim Willis Director, Chemical Control Division, Office of Pollution Prevention and.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
Guidelines for Carcinogen Risk Assessment and Supplemental Guidance for Assessing Cancer Risks from Early-Life Exposures March 29, 2005 Hugh A. Barton,
Understanding Research Articles Microbiology Laboratory.
Elements of a clinical trial research protocol
Measles Mumps Rubella Vaccine May Be Causing Autism Julie Briggs.
ANGLOPHONE WEST AFRICA WORKSHOP ON MERCURY IN ASGM, LAGOS NIGERIA. 8 – 10 JUNE 2011 NATIONAL SITUATION – NIGERIA BY ABIOLA IFUEKO OLANIPEKUN FEDERAL MINISTRY.
Research methods and Critical thinking
Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
ELIZABETH WILLIAMS, MD FELLOW IN VACCINOLOGY AND VACCINE SAFETY VANDERBILT UNIVERSITY AUGUST 30 TH, 2012 Thimerosal and Vaccine Safety.
EVIDENCE-BASED PRACTICE
Safeguarding Animal Health 1 Proposed BSE Comprehensive Rule: A New Approach to BSE Rulemaking Dr. Christopher Robinson Assistant Director, NCIE BSE Comprehensive.
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases Centers.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Presented DATE to GROUP NAME The Great Lakes Border Health Initiative.
Discussion Gitanjali Batmanabane MD PhD. Do you look like this?
Environmental Issues and Cancer Prevention Strategies.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
DrugEpi 1-4 Counting HS Marijuana Use Module 1 Overview Context Content Area: Descriptive Epidemiology & Surveillance Essential Question (Generic): How.
What’s in the news right now related to science???? Flesh eating bacteria.
1 Sex/Gender and Minority Inclusion in NIH Clinical Research What Investigators Need to Know! Presenter: Miriam F. Kelty, PhD, National Institute on Aging,
Application in professional activity of theoretical knowledge and practical skills acquired during residency program Dr. Ion Bîrcă National Center of Public.
Scientific Inquiry & Skills
CSCOPE Unit 14 Lesson 01 SCIENTIFIC INQUIRY AND EXPERIMENTAL DESIGN.
Smallpox Vaccine Program: Communications with the Public and Stakeholders Department of Health and Human Services Centers for Disease Control and Prevention.
Vaccine Safety Working Group Update NVAC Meeting June 2, 2010 Tawny Buck Co-Chair, Vaccine Safety Working Group.
THE ROLE OF DSMB’s in CLINICAL RESEARCH Data and Safety Monitoring Monitoring.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
“MENTAL HEALTH LITERACY AND POSTPARTUM DEPRESSION: A QUALITATIVE DESCRIPTION OF VIEWS OF LOWER INCOME WOMEN” – GUY (2014) -Jasmine R.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.
Characterizing evidence in EMF risk assessment, Berlin, 4-5 May 2006 The WHO International EMF Project Dr E. van Deventer Radiation and Environmental Health.
MATOC Trial Phase Dec 2008 to Jun 2009 Presentation to the Transportation Planning Board Richard W. Steeg, PE Chair MATOC Steering Committee VDOT Regional.
EXPERIMENTAL EPIDEMIOLOGY
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
Grant Application Process Maternal, Infant & Early Childhood Home Visiting Programs.
Nursing research provides the foundation for EVIDENCE-BASED NURSING PRACTICE.
Investigational Devices and Humanitarian Use Devices June 2007.
NVAC H1N1 Vaccine Safety Risk Assessment Working Group (VSRAWG) Update NVAC Meeting June 2, 2010 Marie McCormick, M.D., Sc.D. Sumner and Esther Feldberg.
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
October 11, 2007 Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
CITEL – San Salvador | 16 April | Electromagnetic Fields: A WHO Perspective Dr E. van Deventer.
Strengthening Research Capabilities Professor John B. Kaneene DVM, MPH, PhD, FAES, FAVES Center for Comparative Epidemiology Michigan State University.
HEALTH IMPACT ASSESSMENT: WHAT WE SHOULD DO IN MEXICO JULIETA PISANTY-LEVY.
Childhood Neglect: Improving Outcomes for Children Presentation P28 Childhood Neglect: Improving Outcomes for Children Presentation Understanding cumulative.
Zika Response Strategy
Healthy Children for the Next Generations Engaging Policymakers in Children’s Environmental Health Presentation to the NB Commission on Hydraulic Fracturing.
Has been broadly defined as the generation of new knowledge using the scientific method to identify and deal with health problems.
HSRB Criteria for Review of Pre-Rule Intentional Dosing Studies Sean Philpott, PhD, MSBioethics HSRB Chair June 24, 2009.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary of November 2010 ACBSA for FDA’s BPAC December 2010 CDR Richard Henry, USPHS.
Vaccine Safety Research, Data Access, and Public Trust Findings and Recommendations from IOM NVAC Meeting June 8, 2005 Debra Lappin, J.D. Senior Advisor,
Web Evaluation Examples Library 10 –Information Competency.
IS THERE A LINK BETWEEN VACCINATION AND AUTISM NO Maggie Hague.
H1N1 Vaccine Safety Subgroup: Draft Recommendations to NVAC NVAC Teleconference July 27, 2009 Daniel Salmon Vaccine Safety Specialist National Vaccine.
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
Claims, Evidence, and Reasoning NGSS: SEP # 7 Engaging in argumentation from evidence E5: Read, write, and speak grounded in evidence M3 & E4: Construct.
Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects William W. Thompson, PhD Presented at the.
Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-matched Controls: A Population-Based Study in Metropolitan Atlanta F.
9. Introduction to signal detection
Flu Shots for Health Care Providers – A Strategy That Works
Critical Appraisal วิจารณญาณ
Presentation transcript:

Immunization Safety Review: Vaccines and Autism Marie McCormick Chair, Immunization Safety Review Committee Presentation to NVAC June 2004

Issue Under Review Hypothesized association between vaccines and autism, specifically: MMR vaccine and autism Thimerosal-containing vaccines and autism The committee did not focus on other neurodevelopmental disorders

Why the committee focused on this topic Requested by the Interagency Vaccine Group to reexamine this issue in its eighth and final report. –The committee issued two previous reports in 2001 examining MMR and autism and thimerosal-containing vaccines and neurodevelopmental disorders. Updated statement from the committee was warranted because significant new data have emerged, and because the topic remains of such considerable controversy.

Scientific Assessment: Causality Conclusions The evidence favors rejection of a causal relation between both MMR vaccine and thimerosal-containing vaccines and autism.

Scientific Assessment: Causality Conclusions Evidence for MMR and autism finding: 14 large, well-designed epidemiological studies consistently showed no association between the MMR vaccine and autism. This finding is consistent with 2001 report on MMR and autism

Scientific Assessment: Causality Conclusions Evidence for thimerosal and autism finding: 5 large, well-designed epidemiological studies in different countries provided significant evidence of no association between TCVs and autism IOM report concluded evidence was inadequate to accept or reject relationship between TCVs and NDDs. Why different now? –Only one unpublished epi study available then. Significantly more research available now. –That report focused on broader set of neurodevelopmental outcomes. A potential biological mechanism exists for those outcomes by way of analogy with methyl mercury, but not for autism

Scientific Assessment: Biological Mechanisms Potential biological mechanisms put forth as possible explanations for how vaccines might cause autism: –The release of chemicals into the brain due to disruption of intestinal function by the MMR vaccine –Triggering of abnormalities in the immune system that are indicative of vaccine-induced damage to the CNS –Increased accumulation of and decreased excretion of mercury from the brains of a subgroup of children –The effects of thimerosal on a variety of biochemical pathways

Scientific Assessment: Biological Mechanisms Evidence comes from in vitro experimental systems, clinical observations, and analogies between rodent behavior and human behavior. While the laboratory observations of the toxic effects of mercury are important, these observations do not explain how specific exposures in a rapidly developing infant affect certain tissues but not others where these mechanisms are also active. Laboratory studies also have not shown how these effects lead to autism.

Scientific Assessment: Biological Mechanisms Conclusion In the absence of experimental or human evidence that either the MMR vaccine or vaccines containing thimerosal affect metabolic, developmental, immune, or other physiological or molecular mechanisms that are causally related to the development of autism, the committee concludes that the hypotheses generated to date are theoretical only.

Significance Assessment The committee concludes that because autism can be such a devastating condition, any speculation that links vaccine and autism means that this is a significant issue.

Recommendations for Public Health Response The committee recommends a public health response that fully supports an array of vaccine safety activities. The committee recommends that available for funding for autism research be channeled to the most promising areas.

Recommendations for Public Health Response: Policy Review No policy review of the licensure of the MMR vaccine or thimerosal-containing vaccines and or of current schedule and recommendations for administration of those vaccines.

Recommendations for Surveillance and Epidemiological Research Use standard and accepted case definitions and assessment protocols for ASD Conduct clinical and epidemiological studies of sufficient rigor to identify risk factors and biological markers of ASD Strengthen surveillance of adverse events –e.g., standardize case definitions of adverse events; establish guidelines for use of VAERS; continue use of large linked databases and other tools; further develop of CISA.

Recommendations for Surveillance and Epidemiological Research (cont.) Conduct surveillance of ASD as exposure to thimerosal declines Increase efforts to quantify level of prenatal and postnatal exposure to thimerosal and other forms of mercury in infants, children, and pregnant women

Recommendations for Clinical Studies Because chelation therapy has potentially serious risks, the committee recommends that it be used only in carefully-controlled research settings with appropriate oversight by Institutional Review Boards protecting the interests of children who participate.

Recommendations for Communication Develop programs to increase public participation in vaccine safety research and policy decisions AND to enhance the skills and willingness of scientists and government officials to engage in constructive dialogue with the public about research findings and their implications for policy development.

Contact Information Phone: (202) Website: